Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/16
출원번호
UP-0887204
(2001-06-22)
등록번호
US-7674480
(2010-04-21)
발명자
/ 주소
Fleshner-Barak, Moshe
Lerner, E. Itzhak
Rosenberger, Vered
Dahan, Mazal
Makov, Yisrael
출원인 / 주소
Teva Pharmaceutical Industries Ltd.
대리인 / 주소
Kenyon & Kenyon LLP
인용정보
피인용 횟수 :
1인용 특허 :
59
초록▼
The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention
The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical dosage forms containing an active ingredient, and the pharmaceutical composition. The forms are adapted for immediate or controlled release of the active ingredient. The dosage forms may be used advantageously in the treatment of Parkinson's disease with levodopa and hyperactivity and attention deficit disorder with methylphenidate.
대표청구항▼
What is claimed is: 1. A pharmaceutical dosage form for oral administration to a patient providing pulsed gastric release of methylphenidate comprising: a) a gastric retention vehicle composition comprising about 10 wt-% to about 75 wt-% superdisintegrant, about 2 wt-% to about 12 wt-% tannic acid,
What is claimed is: 1. A pharmaceutical dosage form for oral administration to a patient providing pulsed gastric release of methylphenidate comprising: a) a gastric retention vehicle composition comprising about 10 wt-% to about 75 wt-% superdisintegrant, about 2 wt-% to about 12 wt-% tannic acid, and about 20 to about 70 wt-% of a hydrogel, whereby the gastric retention vehicle composition is a homogenous solid matrix and the percentages are calculated with respect to the matrix exclusive of other excipients and the methylphenidate, b) a plurality of first particles containing methylphenidate that are dispersed in the matrix, wherein the methylphenidate is released from the first particles into the stomach upon contact with gastric fluid, and c) a plurality of second particles containing methylphenidate that are dispersed in the matrix, wherein each of the second particles is coated with a coating that is impermeable to methylphenidate and dissolves in gastric fluid, and, after a sufficient amount of the coating is dissolved, the methylphenidate is released from the second particles into the stomach, wherein, upon contact with gastric fluid the gastric retention vehicle composition expands to a sufficient degree such that the dosage form is retained in the stomach at least until methylphenidate is released from the second particles. 2. A pharmaceutical dosage form of claim 1 further comprising a plurality of third particles containing methylphenidate that are dispersed in the matrix, wherein each of the third particles is coated with a coating that is impermeable to the methylphenidate and dissolves in gastric fluid and the methylphenidate is released from the third particles into the stomach after the methylphenidate is released from the second particles. 3. The pharmaceutical dosage form of claim 2, wherein the methylphenidate is released from the third particles into the stomach about 3 to about 5 hours after the methylphenidate is released from the second particles. 4. A pharmaceutical dosage form of claim 1 wherein the first particles are coated with a coating that delays release of the methylphenidate from said first particles, with the proviso that the first particles and the second particles are not released at the same time. 5. The pharmaceutical dosage form of claim 1, wherein the methylphenidate is released from the second particles into the stomach about 3 to about 5 hours after administration. 6. A method of treating hyperactivity or attention deficit disorder comprising administering a therapeutically effective amount of methylphenidate in the pharmaceutical dosage form of claim 1 to a patient in need thereof. 7. The pharmaceutical dosage form of claim 1, wherein the coating comprises a film coating agent selected from the group consisting of water soluble resins, water insoluble resins, waxes, lipids, and enteric resins. 8. The pharmaceutical dosage form of claim 1, wherein the superdisintegrant is selected from the group consisting of cross-linked carboxymethylcellulose sodium, sodium starch glycolate, and cross-linked polyvinyl pyrollidone. 9. The pharmaceutical dosage form of claim 1, wherein the hydrogel is hydroxypropyl methyl cellulose or a mixture of hydroxypropyl methyl cellulose and hydroxypropyl cellulose or a cross-linked acrylate polymer. 10. The pharmaceutical dosage form of claim 1, comprising from about 10 wt. % to about 30 wt. % hydroxypropyl methylcellulose, from about 40 wt. % to about 60 wt. % hydroxypropyl cellulose, and about 4 wt. % to about 12 wt. % tannic acid. 11. The pharmaceutical dosage form of claim 1, comprising from about 10 wt. % to about 20 wt. % hydroxypropyl methylcellulose, from about 45 wt. % to about 50 wt. % hydroxypropyl cellulose, and about 4 wt. % to about 6 wt. % tannic acid. 12. A pharmaceutical dosage form for oral administration to a patient providing pulsed gastric release of methylphenidate comprising: a) a gastric retention vehicle composition comprising about 20 wt-% to about 70 wt-% of a hydrogel, about 10 wt-% to about 75 wt-% superdisintegrant and about 2 wt-% to about 12 wt-% tannic acid, the percentages calculated exclusive of other excipients or the methylphenidate, b) a first reservoir containing methylphenidate embedded in said gastric retention vehicle composition wherein methylphenidate is released from the first reservoir into the stomach upon contact of the dosage form with gastric fluid, and c) a second reservoir containing methylphenidate embedded in said gastric retention vehicle composition, wherein the second reservoir is coated with a coating that is impermeable to methylphenidate and dissolves in gastric fluid, and, after a sufficient amount of the coating is dissolved, the methylphenidate is released from the second reservoir into the stomach, wherein, upon contact with gastric fluid the gastric retention vehicle composition expands to a sufficient degree such that the dosage form is retained in the stomach at least until methylphenidate is released from the second reservoir. 13. A pharmaceutical dosage form of claim 12 further comprising a third reservoir containing methylphenidate coated with a coating that is impermeable to methylphenidate and dissolves in gastric fluid, wherein the methylphenidate is released from the third reservoir into the stomach after the methylphenidate is released from the second reservoir. 14. A pharmaceutical dosage form of claim 12 wherein the first reservoir is coated with a coating that delays release of the methylphenidate from said first reservoir. 15. A pharmaceutical dosage form of claim 12 wherein the gastric retention vehicle composition and the reservoirs are encapsulated. 16. The pharmaceutical dosage form of claim 12, wherein the methylphenidate is released from the second reservoir about 3 to about 5 hours after administration. 17. A method of treating hyperactivity or attention deficit disorder comprising administering a therapeutically effective amount of methylphenidate in the pharmaceutical dosage form of claim 12 to a patient in need thereof. 18. The pharmaceutical dosage form of claim 12, wherein the coating comprises polymethacrylate, or a mixture of hydrophilic and hydrophobic film forming agents. 19. The pharmaceutical dosage form of claim 18, wherein the hydrophilic film forming agent is selected from the group consisting of methyl cellulose, hydroxypropyl methylcellulose, cellulose phthalate, cellulose acetate phthalate, and polyvinyl alcohol. 20. The pharmaceutical dosage form of claim 18, wherein the hydrophobic film forming agent is selected from the group consisting of ethyl cellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, polyvinyl alcohol maleic anhydride copolymers, β-pinen polymers rosin, partially hydrogenated rosin, and glycerol esters of rosin. 21. The pharmaceutical dosage form of claim 12, wherein the superdisintegrant is selected from the group consisting of cross-linked carboxymethylcellulose sodium, sodium starch glycolate, and cross-linked polyvinyl pyrollidone. 22. The pharmaceutical dosage form of claim 12, wherein the hydrogel is hydroxypropyl methyl cellulose or a mixture of hydroxypropyl methyl cellulose and hydroxypropyl cellulose or a cross-linked acrylate polymer. 23. The pharmaceutical dosage form of claim 12, comprising from about 10 wt. % to about 30 wt. % hydroxypropyl methylcellulose, from about 40 wt. % to about 60 wt. % hydroxypropyl cellulose, and about 4 wt. % to about 12 wt. % tannic acid. 24. The pharmaceutical dosage form of claim 12, comprising from about 10 wt. % to about 20 wt. % hydroxypropyl methylcellulose, from about 45 wt. % to about 50 wt. % hydroxypropyl cellulose, and about 4 wt. % to about 6 wt. % tannic acid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (59)
Shih, Chung; Zentner, Gaylen, Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles.
Moshe Flashner-Barak IL; Vered Rosenberger IL; Mazal Dahan IL; Yitzhak Lerner IL, Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates.
Juan Mantelle ; Terese A. Dixon, Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate.
Mantelle Juan ; Dixon Terese A., Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate.
Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
Thinnayam N. Krishnamurthy CA; Andrew Darke CA, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use.
Caldwell Larry J. (Lawrence KS) Gardner Colin R. (Lawrence KS) Cargill Robyn C. (Lawrence KS), Drug delivery device which can be retained in the stomach for a controlled period of time.
Caldwell Larry J. (Lawrence KS) Gardner Colin R. (Lawrence KS) Cargill Robyn C. (Lawrence KS) Higuchi Takeru (Lawrence KS), Drug delivery device which can be retained in the stomach for a controlled period of time.
Urquhart John (Palo Alto CA) Theeuews Felix (Los Altos CA), Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills.
Gehrke Stevin H. (Cincinnati OH) Lupton E. C. (Boston MA) Schiller Matthew E. (Waltham MA) Uhden Lorelle (Cincinnati OH) Vaid Nitin (Kanpur INX), Enhanced loading of solutes into polymer gels.
Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills.
Park Kinam ; Chen Jun ; Park Haesun, Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties.
Fahn Stanley (155 Edgars La. Hastings-on-Hudson NY 10706), Method and compositions of treating Parkinsonisms with levodopa and 3′,4′-dihydroxy-2-methylisopropiophenone.
Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Weyers, Richard G.; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Hatamkhany, Zah, Methods and devices for providing prolonged drug therapy.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Burnside Beth A. ; Guo Xiaodi ; Fiske Kimberly ; Couch Richard A. ; Treacy Donald J. ; Chang Rong-Kun ; McGuinness Charlotte ; Rudnic Edward M., Oral pulsed dose drug delivery system.
Talwar Naresh,INX ; Sen Himadri,INX ; Staniforth John N.,GBX, Orally administered controlled drug delivery system providing temporal and spatial control.
Conte Ubaldo,ITX ; Maggi Lauretta,ITX, Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids.
Panoz Donald (Tuckerstown BMX) Corneille Gilbert (Paris FRX), Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained the.
Wong Patrick S. L. ; Dong Liang-Chang ; Edgren David E. ; Theeuwes Felix ; Gardner Phyllis I. ; Jao Francisco ; Wan Jason J., Prolonged release active agent dosage form adapted for gastric retention.
Himmelstein Kenneth J. (Omaha NE) Baustian Cara L. (Pearl River NY 4), Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use.
Gaylord Norman G. (New Providence NJ) Nigalaye Ashok (East Rockaway NY), Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates.
Lovegrove Claire J. (Ware GB2) Rawlins David A. (Tewin GB2) Phillips Anthony J. (Little Hadham GB2) Tainsh David A. (Buntingford GB2), Sustained release pharmaceutical compositions in oral dosage form.
Kim, In-Ae; Kim, Sang-Hee; Jung, Ji-Hoon; Chang, Hee-Chul; Maeng, Jin-Hee; Yang, Su-Geun; Lee, Don-Haeng; Min, Kyung-Hyun, Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.